The recent CHANCE-2 trial in China showed that among patients with TIA or minor ischemic stroke who were carriers of CYP2C19 loss-of-function alleles, the risk of stroke at 90 days in the ticagrelor group was modestly lower than that in the clopidogrel group. The gene discussed is CYP2C19; the disease is stroke disorder.